{"disease":{"id":"epithelioid-sarcoma","name":"Epithelioid sarcoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"tazemetostat","indication_name":"Epithelioid Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"tazemetostat","indication_name":"Epithelioid sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"chembl-chembl3414621","indication_name":"Epithelioid sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"TAZEMETOSTAT","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of an enzyme called EED, which is involved in the production of proteins that promote cancer growth."},{"drug_id":"tazverik","indication_name":"Epithelioid sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tazverik","company_name":"Edwin Posadas, MD","drug_phase":"discontinued","molecular_target":"Polycomb protein EED, Histone-lysine N-methyltransferase EZH1, Histone-lysine N-methyltransferase EZH2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00346164","title":"Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02601950","title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":267,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT04390737","title":"Evaluate the Safety and Clinical Activity of HH2853","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":254,"lead_sponsor_name":"Haihe Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT02180867","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01064648","title":"Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06408441","title":"The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT03099681","title":"An Observational Study on Epithelioid Sarcoma","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Italian Sarcoma Group","has_results":false},{"nct_id":"NCT05415098","title":"Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT05286801","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03837678","title":"Epithelioid Sarcoma Natural History Study","phase":"","overall_status":"COMPLETED","enrollment_count":74,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT02584309","title":"Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT02399371","title":"Pembrolizumab in Treating Patients With Malignant Mesothelioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":65,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT01532687","title":"Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT05407441","title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"Susan Chi, MD","has_results":false},{"nct_id":"NCT01614795","title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04537715","title":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT00112463","title":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03190174","title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Sarcoma Oncology Research Center, LLC","has_results":true},{"nct_id":"NCT04008238","title":"Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04204941","title":"Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT03009201","title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04225429","title":"Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT07502716","title":"Compassionate Use of Ubamatamab","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03874455","title":"Tazemetostat Expanded Access Program for Adults With Solid Tumors","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Epizyme, Inc.","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}